|
KMID : 1195620180110040217
|
|
Clinical and Experimental Otorhinolaryngology
2018 Volume.11 No. 4 p.217 ~ p.223
|
|
|
Immunotherapy in Head and Neck Squamous Cell Cancer
|
|
Denaro Nerina
Merlano Marco Carlo
|
|
|
Abstract
|
|
|
|
Prognosis in relapsed metastatic head and neck squamous cell cancer (RM-HNSCC) is dismal. Platinum based chemotherapy in combination with Cetuximab is used in first-line setting, while no further validated options are available at progression. Immunotherapy has produced durable clinical benefit in some patients with RM-HNSCC although the premises are several patients are nonresponders. Studies are ongoing to determine predictive factors and the ideal setting/combination of novel immunotherapies. In this paper, we discuss the past and present of immunotherapy in head and neck cancer and provide an up-to-date information regarding the potential ways to improve immunotherapy outcomes in HNSCC.
|
|
|
KEYWORD
|
|
|
Immunotherapy, Tumor Immune Escape, Squamous Cell Carcinoma, Head And Neck, Biomarkers
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|